164 related articles for article (PubMed ID: 37663284)
1. RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA.
Fan J; Zhuang M; Fan W; Hou M
PeerJ; 2023; 11():e15706. PubMed ID: 37663284
[TBL] [Abstract][Full Text] [Related]
2. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability.
Zhang N; Shen Y; Li H; Chen Y; Zhang P; Lou S; Deng J
Exp Mol Med; 2022 Feb; 54(2):194-205. PubMed ID: 35217832
[TBL] [Abstract][Full Text] [Related]
3. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
[TBL] [Abstract][Full Text] [Related]
4. m
Zhao Y; Zhou Y; Qian Y; Wei W; Lin X; Mao S; Sun J; Jin J
Clin Transl Med; 2024 Apr; 14(4):e1628. PubMed ID: 38572589
[TBL] [Abstract][Full Text] [Related]
5. N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2.
Wen D; Xiao H; Gao Y; Zeng H; Deng J
Mol Cancer; 2024 May; 23(1):116. PubMed ID: 38822351
[TBL] [Abstract][Full Text] [Related]
6. IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signalling pathway in human bladder cancer.
Huang W; Li Y; Zhang C; Zha H; Zhou X; Fu B; Guo J; Wang G
J Cell Mol Med; 2020 Dec; 24(23):13949-13960. PubMed ID: 33094561
[TBL] [Abstract][Full Text] [Related]
7. m6A genotypes and prognostic signature for assessing the prognosis of patients with acute myeloid leukemia.
Fu C; Kou R; Meng J; Jiang D; Zhong R; Dong M
BMC Med Genomics; 2023 Aug; 16(1):191. PubMed ID: 37596597
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic Value of
LE N; Yang JJ; Liu YC; Zhang XW; Wang H; Wen YN; Jiao YF; Wang LL; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):355-364. PubMed ID: 38660836
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
Ji G; Huang C; He S; Gong Y; Song G; Li X; Zhou L
Aging (Albany NY); 2020 Jul; 12(14):14863-14884. PubMed ID: 32710725
[TBL] [Abstract][Full Text] [Related]
11. RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.
Zhu K; Gao T; Wang Z; Zhang L; Tan K; Lv Z
Cell Death Discov; 2023 May; 9(1):151. PubMed ID: 37156775
[TBL] [Abstract][Full Text] [Related]
12. The RNA m6A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression.
Hong YG; Yang Z; Chen Y; Liu T; Zheng Y; Zhou C; Wu GC; Chen Y; Xia J; Wen R; Liu W; Zhao Y; Chen J; Gao X; Chen Z
Cancer Res; 2023 Mar; 83(6):845-860. PubMed ID: 36634204
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of
Guo W; Huai Q; Wan H; Guo L; Song P; Gao S; He J
DNA Cell Biol; 2021 Feb; 40(2):316-331. PubMed ID: 33493403
[TBL] [Abstract][Full Text] [Related]
14. IGF2BP3/HIF1A/YAP signaling plays a role in driving acute-on-chronic liver failure through activating hepatocyte reprogramming.
Cheng K; Liu S; Li C; Zhao Y; Wang Q
Cell Signal; 2023 Aug; 108():110727. PubMed ID: 37257765
[TBL] [Abstract][Full Text] [Related]
15. Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.
Wu T; Zhang X; Xing L; Pan D; Liu P; Ding R; Yang R; Yang X; Li Y
Dis Markers; 2022; 2022():5883101. PubMed ID: 35677634
[TBL] [Abstract][Full Text] [Related]
16. Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes.
Wang Y; Bin T; Tang J; Xu XJ; Lin C; Lu B; Sun TT
Front Immunol; 2023; 14():1268090. PubMed ID: 38077322
[TBL] [Abstract][Full Text] [Related]
17. N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-κB pathways.
Xiao K; Liu P; Yan P; Liu Y; Song L; Liu Y; Xie L
Bioengineered; 2022 May; 13(5):11973-11986. PubMed ID: 34709120
[TBL] [Abstract][Full Text] [Related]
18. [Characteristics of N6-methyladenosine modification patterns in t(8;21) acute myeloid leukemia].
Wen Y; Fang S; Yang J; Wang H; Jiao Y; Wang N; Wei Y; Wang L; Dou L
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):690-697. PubMed ID: 35673912
[TBL] [Abstract][Full Text] [Related]
19. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
[TBL] [Abstract][Full Text] [Related]
20. Identification of m6A-Related lncRNAs Associated With Prognoses and Immune Responses in Acute Myeloid Leukemia.
Li D; Liang J; Cheng C; Guo W; Li S; Song W; Song Z; Bai Y; Zhang Y; Wu X; Zhang W
Front Cell Dev Biol; 2021; 9():770451. PubMed ID: 34869365
[No Abstract] [Full Text] [Related]
[Next] [New Search]
